Clovis Oncology Inc (NASDAQ:CLVS) announced that comprehensive data from the Phase 3 ARIEL3 study of rucaparib for maintenance treatment of advanced ovarian cancer …
J.P.
The FDA approved this morning a new indication for AstraZeneca’s (NYSE:AZN) ARP inhibitor Lynparza. The new indication is for use in patients with recurrent …
Clovis Oncology Inc (NASDAQ:CLVS) announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds …
Novadaq Technologies Inc. Novadaq Technologies Inc.
Clovis Oncology Inc (NASDAQ:CLVS) announced that the underwriters of its recently announced public offering of its common stock have exercised in full their …
Piper Jaffray analyst Steven Breazzano remains sidelined, but optimistic on Clovis Oncology Inc (NASDAQ:CLVS) following the firm’s conference call discussing FDA approval of …
Clovis Oncology Inc (NASDAQ:CLVS) announced that the U.S.
